Providing GLP-1 drugs to 19.7 million Medicare beneficiaries with obesity would cost $268 billion a year, researchers estimate in a recent study.
Originally posted 2024-05-29 12:01:25.
https://adventurehealthcare.net/
https://adventurehealthcare.net/
Originally posted 2024-05-29 12:01:25.
